Encompass Health Reports Strong Q2 Results, Raises Full-Year Guidance, Boosts Share Buyback to $1B
EHC sits 19% above its 52-week low of $92.77.
Summary
Encompass Health announced strong Q2 2026 results, including significant revenue and earnings growth, and raised its full-year guidance. The company also increased its share repurchase authorization to $1 billion.
Updates
· SEC 10-Q — The 10-Q reports Q2 net income attributable to Encompass Health of $153.9 million, or $1.54 diluted EPS, and six-month net income of $348.4 million, or $3.47 diluted EPS.
· Reuters — Q2 revenue rose 9.6% to $1.6B, adjusted EPS $1.55 beat $1.48 consensus; full-year guidance raised to revenue $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, adjusted EPS $6.02-$6.25; buyback authorization expanded to $1B.
Key Events · Earnings and Guidance · EHC
-
Strong Q2 Financial Performance
Net operating revenue increased 9.6% to $1.597 billion, Adjusted EBITDA grew 9.2% to $348.0 million, and adjusted earnings per share rose 10.7% to $1.55 for the second quarter ended June 30, 2026.
-
Full-Year Guidance Raised
The company increased its full-year 2026 guidance for net operating revenue to $6.410 billion-$6.490 billion, Adjusted EBITDA to $1.365 billion-$1.395 billion, and adjusted earnings per share to $6.02-$6.25.
-
Share Repurchase Authorization Increased
The board of directors approved an increase in the aggregate common stock repurchase authorization to $1 billion. The company had repurchased $145.8 million year-to-date and had approximately $188 million remaining under the prior authorization as of June 30, 2026.
Analysis · EHC · Industrial Applications And Services
Encompass Health reported robust second-quarter financial results, with significant increases in net operating revenue, Adjusted EBITDA, and adjusted earnings per share. The company also raised its full-year 2026 guidance across all key financial metrics, signaling strong operational performance and management confidence. Additionally, the board approved a substantial increase in the common stock repurchase authorization to $1 billion, demonstrating a commitment to returning capital to shareholders and confidence in the company's valuation.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EHC was trading at $110.73 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $11B. The 52-week trading range was $92.77 to $127.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.